ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026)
ENDRA Life Sciences (NDRA) reported Cash from Financing Activities of $263747.0 for Q1 2026, up 80.89% year-over-year from $145803.0 in Q1 2025, and down 94.24% quarter-over-quarter from $4.6 million in Q4 2025.
ENDRA Life Sciences (NDRA) Cash from Financing Activities (2016 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has 11 years of Cash from Financing Activities data on file, last reported at $263747.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $263747.0, up 80.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 million (down 21.84% YoY), and the FY2025 annual result was $5.7 million, down 26.59% from the prior year.
- Cash from Financing Activities declined to $263747.0 in Q1 2026 per NDRA's latest filing, from $4.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.5 million in Q2 2022 and troughed at $1683.0 in Q3 2024.
- A 5-year average of $2.3 million and a median of $857415.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities plunged 99.85% in 2024, then surged 8780.93% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $7.5 million in 2022, then plunged by 77.85% to $1.7 million in 2023, then tumbled by 99.9% to $1683.0 in 2024, then jumped by 272035.41% to $4.6 million in 2025, then sank by 94.24% to $263747.0 in 2026.
- Business Quant data shows NDRA's Cash from Financing Activities at $263747.0 in Q1 2026, $4.6 million in Q4 2025, and $149466.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn | -213.00 Mn |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn | 1.09 Bn |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn | 46.00 Mn |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn | -211.43 Mn |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn | -144.00 Mn |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn | 3.76 Mn |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn | -433.00 Mn |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn | -251.00 Mn |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn | -114.33 Mn |
| 10 | ENDRA Life Sciences | 5.24 Mn | 4.89 Mn | - | 263,747.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 263,747.00 |
| Mar 31, 2026 | 263,747.00 |
| Dec 31, 2025 | 4.58 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 149,466.00 |
| Sep 30, 2025 | 149,466.00 |
| Jun 30, 2025 | 857,415.00 |
| Jun 30, 2025 | 857,415.00 |
| Mar 31, 2025 | 145,803.00 |
| Mar 31, 2025 | 145,803.00 |
| Sep 30, 2024 | 1,683.00 |
| Sep 30, 2024 | 1,683.00 |
| Jun 30, 2024 | 7.34 Mn |
| Jun 30, 2024 | 7.34 Mn |
| Mar 31, 2024 | 468,902.00 |
| Mar 31, 2024 | 468,902.00 |
| Dec 31, 2023 | 1.67 Mn |
| Dec 31, 2023 | 1.67 Mn |
| Sep 30, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.11 Mn |